Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I

Recruiting now · Phase 1/Phase 2

Conditions studied: Anti-cancer Cell Immunotherapy, T Cell and NK Cell

In brief

T effector cells and NK cells have mutual compensatory killing functions on various of cancer types. For those cancers that have no available targets for CAR-T cell generations, we established potent T cell-like NK cells (ITNK) with a specific conversion protocol for the T cells from the patient, to perform anti-cancer therapy, especially for those cancers that are lack of MHC-I molecule expression. We have finished pre-clinical investigations for the ITNK or CAR-ITNK cell therapy and scheduled to start a clinical phase I study.

Key facts

Study ID
NCT03882840
Run by
Second Affiliated Hospital of Guangzhou Medical University
People needed
60
Starts
2019-01-01
Expected to finish
2035-01-01
Last updated by the study team
2024-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.